# Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease

Study · id `cardio:ct-nct06932874` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06932874](<https://clinicaltrials.gov/study/NCT06932874>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06932874

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 356 participants.

## Technical summary

Registry record NCT06932874. Randomized; no masking; primary purpose treatment. Start 2025-03-04 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 356 participants (planned count; ClinicalTrials.gov record NCT06932874, source copy `cardio:ctgov-nct06932874-2025-04-30`, retrieved 2026-10-26)
- Started: 2025-03-04 (actual) (ClinicalTrials.gov record NCT06932874, source copy `cardio:ctgov-nct06932874-2025-04-30`, retrieved 2026-10-26)
- Primary completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06932874, source copy `cardio:ctgov-nct06932874-2025-04-30`, retrieved 2026-10-26)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT06932874, source copy `cardio:ctgov-nct06932874-2025-04-30`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT06932874, source copy `cardio:ctgov-nct06932874-2025-04-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06932874-2025-04-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: Metformin Hydrochloride Sustained-release Tablets (Ⅲ) in Patients With Type 2 Diabetes Mellitus Complicated With Coronary Heart Disease
- Condition: Atherosclerotic Heart Disease
- Condition: Type 2 Diabetes
- Intervention (Drug): Glucophage (Metformin Hydrochloride Tablets)
- Intervention (Drug): New sustained-release metformin tablets (Ⅲ)
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: cb17a55c8e623f646d3309cc6a713271a3ebe90a821c82e28d19215cd00c03e7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
